Table 1.
Baseline Characteristics of Participants
| Characteristic | HBsAg Positive (n = 28) | HBsAg Negative (n = 272a) | P Value |
|---|---|---|---|
| Age (IQR) years | 35.5 (31.5–42.5) | 36.0 (32–42) | .823 |
| Female (N, %) | 18.0 (64.3) | 174.0 (64.0) | .575 |
| BMI (IQR) | 20.9 (18.9–23.6) | 21.7 (19.1–25.1) | .686 |
| CD4+ T-cell count (cells/mm3) (IQR) | 171.6 (93.3–238.5) | 166.3 (82.1–231.2) | .717 |
| HIV viral load, log copies/mL (IQR) | 4.9 (4.5–5.7) | 5.1 (4.6–5.6) | .603 |
| AST (IU/L) (IQR) | 33.5 (24.4–43.9) | 28.2 (23.0–36.4) | .148 |
| ALT (IU/L) (IQR) | 23.3 (16.0–36.7) | 20.4 (14.8–28.8) | .172 |
| Hemoglobin (g/dL) (IQR) | 11.7 (9.6–13.2) | 11.5 (9.9–12.9) | .981 |
| FIB-4 score (IQR) | 1.08 (0.8–1.5) | 1.0 (0.8–1.4) | .355 |
| Platelets (cells/μL) (IQR) | 245.0 (201.5–300.0) | 262.0 (208.0–316.0) | .462 |
| NNRTI (N, %) | |||
| Nevirapine-based regimen | 15.0 (53.6) | 146.0 (53.7) | |
| Efavirenz-based regimen | 13.0 (46.4) | 126.0 (46.3) | |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FIB, fibrosis; HBsAg, hepatitis B virus surface antigen; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitors.
a One participant died.